Sale

Cancer Immunotherapy Market

Global Cancer Immunotherapy Market Size, Share, Growth, Analysis, Forecast; By Therapy Type: Monoclonal Antibodies, Cancer Vaccines, Immunomodulators, Immune Check Point Inhibitors, Others; By Application: Prostate Cancer, Breast Cancer, Others; By Distribution Channels; By End Use; Regional Analysis; Supplier Landscape; 2024-2032

Global Cancer Immunotherapy Market Outlook

The global cancer immunotherapy market size attained a value of USD 118.97 billion in 2023. The market is likely to grow at a CAGR of 11.6% during the forecast period of 2024-2032 to attain a value of USD 319.45 billion by 2032.

 

Global Cancer Immunotherapy Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Increasing Demand for Monoclonal Antibodies to Catalyse the Growth of the Global Cancer Immunotherapy Industry

Based on therapy type, the monoclonal antibodies segment is expected to hold a significant share in the global cancer immunotherapy industry during the forecast period. This growth can be attributed to the heightened implementation of monoclonal antibodies therapy in cancer treatment globally. Monoclonal antibodies are immune system proteins created in the lab. Antibodies help the immune system to identify disease-causing bacteria and viruses and target them. For example, rituximab binds to a protein called CD20 on B cells, a type of white blood cells, and some types of cancer cells, causing the immune system to attack them. These factors are estimated to drive the market growth in the forecast period.

 

North America to Possess a Substantial Market Share in the Global Cancer Immunotherapy Industry

North America is predicted to hold a considerable market share in the global cancer immunotherapy industry. This surge can be attributed to the increased adoption of cancer immunotherapy in the region. In addition, the growing prevalence of cancer in the region has enhanced the demand for immunotherapies. According to the statistics given by National Cancer Institute, as of January 2019, there were an estimated 16.9 million cancer survivors reported in the United States. Further, the number of cancer survivors is projected to increase to 22.2 million by 2030. These factors are estimated to drive the market growth in the region.

 

Cancer Immunotherapy: Market Segmentation

Cancer refers to diseases that can originate in any organ or tissue of the body where abnormal cells grow unnaturally and go beyond their usual boundaries to invade nearby body parts, also known as metastasizing. According to WHO, cancer is the second leading cause of death globally. Among men, lung, prostate, colorectal, stomach, and liver cancer are the most common types of cancer. In contrast, breast, colorectal, lung, cervical and thyroid cancer are the most common cancer types among women. In this regard, immunotherapy is a treatment for cancer that helps and supports a patient's immune system to fight cancer by providing a boost to the immune system's natural defences to locate and attack cancer cells in the body.

 

Global Cancer Immunotherapy Market by Segment

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

By therapy type, the market is distributed into:

  • Monoclonal Antibodies
  • Cancer Vaccines
  • Immunomodulators
  • Immune Check Point Inhibitors
  • Others

On the basis of application, the industry can be categorised into:

  • Prostate Cancer
  • Breast Cancer 
  • Skin Cancer 
  • Lung Cancer
  • Others

Based on end use, the market can be segmented into:

  • Hospitals and Clinics
  • Cancer Research Centres
  • Others

The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

Global Cancer Immunotherapy Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Heightened Prevalence of Cancer to Augment the Growth of the Global Cancer Immunotherapy Industry

According to the WHO statistics, cancer is the second leading cause of death globally, with around 9.6 million casualties reported in 2018. In 2020, the number of cancer cases reported was 19.3 million, and this number is estimated to rise to 30.2 million by 2040. Among these, the most commonly found cancer is breast cancer. In 2020, an estimated 2.3 million women were diagnosed with breast cancer and 685 000 deaths globally. Observing the growing prevalence of cancer worldwide, governments and international organisations are increasingly devising strategies and conceptualising initiatives to raise funds and awareness about cancer and its potential prevention. For instance, the WHO initiative, Global Breast Cancer Initiative (GBCI), aims to reduce the mortality rate by 2.5% every year, which would help to prevent 40% of cancer deaths by 2040. Their main objectives include health promotion for early detection, timely diagnosis, and comprehensive breast cancer management. Such developments are expected to drive market growth in the forecast period.

 

Key Industry Players in the Global Cancer Immunotherapy Market

The report gives a detailed analysis of the following key players in the global cancer immunotherapy market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG 
  • Others

The comprehensive EMR report provides an in-depth assessment of the industry based on the Porter's five forces model and SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Therapy Type
  • Application
  • Distribution Channels
  • End Use
  • Region
Breakup by Therapy Type
  • Monoclonal Antibodies
  • Cancer Vaccines
  • Immunomodulators
  • Immune Check Point Inhibitors
  • Others
Breakup by Application
  • Prostate Cancer
  • Breast Cancer
  • Skin Cancer
  • Lung Cancer
  • Melanoma
  • Others
Breakup by Distribution Channels
  • Hospitals Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others
Breakup by End Use
  • Hospitals & Clinics
  • Cancer Research Centers
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Genentech, Inc (Roche)
  • Lilly
  • Johnson & Johnson Services, Inc
  • Immunocore, Ltd
  • Merck

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Cancer Immunotherapy Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Cancer Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Cancer Epidemiology (2016-2031)
    5.3    Europe Cancer Epidemiology (2016-2031)
    5.4    Asia-Pacific Cancer Epidemiology (2016-2031)
    5.5    Latin America Cancer Epidemiology (2016-2031)
    5.6    Middle East & Africa Cancer Epidemiology (2016-2031)
6    Global Cancer Immunotherapy Market Overview 
    6.1    Global Cancer Immunotherapy Market Historical Value (2017-2023) 
    6.2    Global Cancer Immunotherapy Market Forecast Value (2024-2032)
7    Global Cancer Immunotherapy Market Landscape
    7.1    Global Cancer Immunotherapy Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Global Cancer Immunotherapy Product Landscape
        7.2.1    Analysis by Therapy Type
        7.2.2    Analysis by End User
        7.2.3    Analysis by Applications
8    Cancer Immunotherapy Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Cancer Immunotherapy Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model 
    10.4    Key Demand Indicators
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends 
    10.7    Value Chain Analysis
11    Global Cancer Immunotherapy Market Segmentation 
    11.1    Global Cancer Immunotherapy Market by Therapy Type
        11.1.1    Market Overview
        11.1.2    Monoclonal Antibodies
        11.1.3    Cancer Vaccines
        11.1.4    Immunomodulators
        11.1.5    Immune Check Point Inhibitors
        11.1.6    Others 
    11.2    Global Cancer Immunotherapy Market by Application
        11.2.1    Market Overview
        11.2.2    Prostate Cancer
        11.2.3    Breast Cancer
        11.2.4    Skin Cancer
        11.2.5    Lung Cancer
        11.2.6    Melanoma
        11.2.7    Others
    11.3    Global Cancer Immunotherapy Market by Distribution Channels
        11.3.1    Market Overview
        11.3.2    Hospitals Pharmacy
        11.3.3    Retail Pharmacy
        11.3.4    Online Pharmacy
        11.3.5    Others
    11.4    Global Cancer Immunotherapy Market by End Use
        11.4.1    Market Overview
        11.4.2    Hospitals & Clinics
        11.4.3    Cancer Research Centers
    11.5    Global Cancer Immunotherapy Market by Region
        11.5.1    Market Overview
        11.5.2    North America 
        11.5.3    Europe
        11.5.4    Asia Pacific
        11.5.5    Latin America
        11.5.6    Middle East and Africa
12    North America Cancer Immunotherapy Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Cancer Immunotherapy Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Cancer Immunotherapy Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Cancer Immunotherapy Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Cancer Immunotherapy Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Patent Analysis
    17.1    Analysis by Type of Patent
    17.2    Analysis by Publication year
    17.3    Analysis by Issuing Authority
    17.4    Analysis by Patent Age
    17.5    Analysis by CPC Analysis
    17.6    Analysis by Patent Valuation 
    17.7    Analysis by Key Players
18    Grants Analysis
    18.1    Analysis by year
    18.2    Analysis by Amount Awarded
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Grant Application
    18.5    Analysis by Funding Institute
    18.6    Analysis by NIH Departments
    18.7    Analysis by Recipient Organization
19    Clinical Trials Analysis 
    19.1     Analysis by Trial Registration Year 
    19.2    Analysis by Trial Status 
    19.3    Analysis by Trial Phase 
    19.4    Analysis by Therapeutic Area 
    19.5    Analysis by Geography
20    Funding Analysis
    20.1    Analysis by Funding Instances
    20.2    Analysis by Type of Funding
    20.3    Analysis by Funding Amount
    20.4    Analysis by Leading Players
    20.5    Analysis by Leading Investors
    20.6    Analysis by Geography
21    Partnership and Collaborations Analysis
    21.1    Analysis by Partnership Instances
    21.2    Analysis by Type of Partnership
    21.3    Analysis by Leading Players
    21.4    Analysis by Geography
22    Regulatory Framework
    22.1    Regulatory Overview
        22.1.1    US FDA
        22.1.2    EU EMA
        22.1.3    INDIA CDSCO
        22.1.4    JAPAN PMDA
        22.1.5    Others
23    Supplier Landscape
    23.1    AstraZeneca
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    F. Hoffmann-La Roche Ltd
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    Amgen Inc.
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4     Astellas Pharma Inc.
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    Bayer AG
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    Bristol-Myers Squibb Company
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    Novartis AG
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Genentech, Inc (Roche)
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Lilly
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    Johnson & Johnson Services, Inc
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
    23.11    Immunocore, Ltd
        23.11.1    Financial Analysis
        23.11.2    Product Portfolio
        23.11.3    Demographic Reach and Achievements
        23.11.4    Mergers and Acquisitions
        23.11.5    Certifications
    23.12    Merck
        23.12.1    Financial Analysis
        23.12.2    Product Portfolio
        23.12.3    Demographic Reach and Achievements
        23.12.4    Mergers and Acquisitions
        23.12.5    Certifications
24    Global Cancer Immunotherapy Market- Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The cancer immunotherapy Market was valued at USD 118.97 billion in 2023.

The market is expected to grow at a CAGR of 11.6% from 2024 to 2032 to reach a value of USD 319.45 billion by 2032.

The major drivers of the industry include rapidly growing geriatric global population, rising numbers of casualties of different cancer varieties, increased adoption of cancer immunotherapy and heightened implementation of monoclonal antibodies therapy in cancer treatment.

The key market trends guiding the industry's growth include the growing prevalence of cancer worldwide and government initiatives to raise funds and awareness about cancer and its potential prevention.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The market is divided based on therapy type into monoclonal antibodies, cancer vaccines, immunomodulators, and immune check point inhibitors, among others.

The significant applications include into prostate cancer, breast cancer, skin cancer, and lung cancer, among others.

The significant segments based on  end-use include hospitals and clinics and cancer research centres, among others.

The major players in the industry are Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, and F. Hoffmann-La Roche AG., among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER